Join | Update Your Details | Contact | Feedback | Site Map
Usdaw
 
Search
Advanced Search
Ask Jan

Newsroom
Campaigns
About us
Join
Helpful resources
Events
Links
Arena magazine
Jobs at Usdaw
Online store
Contact

Find out more about
Legal Plus
Get Active
Lifelong Learning
Member Services
Equality
Health & Safety
Political Campaigns
Pensions

Have your say

At what rate are your household expenses rising? (including all essentials like food, travel, bills etc.)

  Less than 5%
6 - 10%
11 - 15%
16 - 20%
More than 20%
View results
 
Arena Magazine 2006 Issue 3 Summer Arena

In the pink!

As breast cancer drug Herceptin continues to hit the headlines. Arena takes a closer look.

A group of courageous women in Staffordshire are at the forefront of a campaign to make the breast cancer drug Herceptin available on the NHS.

The campaign, started in June last year, has already had remarkable success with seven women now receiving the treatment. The team are now determined to take the campaign nationally.

At the forefront is Dot Griffiths, diagnosed with breast cancer in 2001 and given just six months to live. "It's been an emotional roller-coaster ride for all of our families," she said. "We've gone through the lows of being refused the treatment to the highs of winning our individual battles to be prescribed the drug. It's been exhilarating and humbling at the same time. The support we've had from people has been fantastic. Winning has given us a lifeline."

Lynne Burton, who is now being prescribed Herceptin, believes the drug has made a major improvement to her life. "I'm a direct beneficiary of the campaign," said Lynne, who was treated for cancer in the early '90s. The cancer returned and, like her friends, she has had a complex course of treatment involving radio and chemotherapy. "Having cancer is traumatic enough without being told you are not eligible, for whatever reason, to receive a drug which could help. I was given Herceptin in January this year. It's made a real difference." Elaine Davies is also battling cancer and joined the campaign even though she was prescribed the drug early on in her treatment.

Local Usdaw rep Ellen Shaw and colleague Deb Kane, who work at the Tesco store in Longton, have been heavily involved in the fundraising efforts. "It's a subject close to my heart as Elaine Davies, my sister-in-law, has terminal cancer and has been treated with Herceptin," said Ellen. "Deb and I became involved because we wanted to help other women receive the drug as early as possible. In one instance we had women living within two miles of each other but because they came under different health trusts some were given the drug, others weren't. We know it's a complicated issue but we believe more can be done for women with breast cancer."

More than £70,000 has been raised and is looked after by a specially set up charity. Some of the money has been used to pay for women to receive the drug privately. Cash has also been donated to the cancer unit of a local hospital.

The women have won the support of their local MPs and the press and they have even appeared on the BBC's Panorama programme earlier this year. The team also handed in a 36,000 signature petition at 10 Downing Street last September.

Herceptin: The Facts

  • Herceptin is licensed for the treatment of advanced breast cancer. It is not currently licensed for women with early stage breast cancer.
  • It is not suitable for all breast cancer patients as it only works on particular types of breast cancer cells, which are evident in some women but not all.
  • In clinical trials it has been shown to slow the growth of tumours, increase patient survival time and reduce the number of deaths in women with advanced breast cancer.
  • The cost of the drug ranges from £29,000 - £39,000 a year.
  • In a recent court case Swindon Primary Care Trust said it refused to prescribe Herceptin to Ann Marie Rogers because of the licensing issue not the cost. The Court of Appeal ruled in favour of Mrs Rogers overturning an earlier decision by the High Court.

Latest news

The European Medicines Agency, part of the regulatory process, has rushed through its approval of Herceptin for use in cases of early breast cancer. The final stage of the procedure is likely to be completed within 90 days.

For more information visit:

www.fightingforherceptin.org.uk

www.imaginis.com

www.thisisstaffordshire.co.uk


2006 Issue 3 Summer Arena Contents | Previous Issues


Printer Friendly Page Printer Friendly Page     Email this page to a friend Email to a Friend


  Join | Update Your Details | Contact | Feedback | Site Map | Privacy | Site Survey
Top top

© 2003 (USDAW) Union of Shop, Distributive and Allied Workers
This page: http://www.usdaw.org.uk/arena_journal/21/in_the_pink.html
Last Modified: Wednesday, 24-Jan-2007 01:36:48 EST
Proudly designed and programmed by Social Change Online
Site Credits

USDAW Online